Verification register Bio, Health & Neuro
Current reading
The readiness gap, in one scan
AI-assisted assembly · derived results
- Claimed
- 45
- Reported
- 41
- Verified
- 32
- Gap
- +13
Public ambition and stated capability
Observed practitioner reporting
Independently supported evidence
Claimed minus verified
Evidence strength Strong
Decision
What the current evidence supports
Human editorial judgment · 2026-06-28
Track; not yet
- Why
- Genuinely promising srRNA dose-sparing and durability signals with growing institutional backing (third Gates Foundation grant, Butantan rabies collaboration), but evidence still stops at Phase 1 immunogenicity in healthy adults with no efficacy endpoint or dated pivotal readout.
- Next
- Watch for a registered/registrational Phase 2-3 (efficacy/non-inferiority vs RabAvert, e.g. via Instituto Butantan) and peer-reviewed effect sizes before treating srRNA as a deployable platform signal
Constraints
Blockers
No named blocker is present in the current public projection.
Evidence summary
Derived counts
AI-assisted assembly
- Total
- 7
- Tier 1
- 6
- Tier 2
- 1
- Tier 3
- 0
- Supports
- 4
- Contradicts
- 2
- Context
- 1
- Latest observed
- 2026-06-19
Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.
Publication record
Revisions
Initial public reading
This is the initial public reading. No earlier readiness change is recorded.